Browse grants
Federal opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying.
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Due Nov 30, 2028National Institutes of Health · Amount varies
Current recipients of specific types of NIH research grants may apply for administrative supplements, using this Notice of Funding Opportunity (NOFO), to provide additional funding to a currently funded grant to meet increased costs that are within the scope of the peer-reviewed and approved project, but that were unforeseen when the new or competing renewal application was awarded. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. There is no guarantee that funds are available from the awarding IC or for any specific grant. Therefore, prior to submission, applicants must discuss potential requests with the awarding ICO grants and program officials.
Limited Competition: Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed)
Due Jan 26, 2029National Institutes of Health · $25K–$250K
The Instrumentation Grant Program for Resource-Limited Institutions supports the purchase of state-of-the-art scientific instruments to enhance the research and educational missions of resource-limited institutions. Requested instruments may support biomedical research and education in basic, translational, biomedically-related behavioral or clinical fields. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.
Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed)
Due Jan 29, 2029National Institutes of Health · Amount varies
This Notice of Funding Opportunity (NOFO) encourages applications for NIGMS Biomedical Technology Optimization and Dissemination (BTOD) Centers to support late-stage technology optimization and sustainable dissemination of the technologies to the wider biomedical research community. A BTOD Center should be at the leading edge of its field with respect to both technology optimization and engagement with relevant research communities.BTOD projects must address biomedical research areas within the NIGMS mission. Potential applicants are strongly encouraged to consult with NIGMS staff about adherence of their proposed research strategy to the Institute's goals and mission and its responsiveness to this NOFO.
Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (ESI)
Due Feb 6, 2029National Institutes of Health · Amount varies
The Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (ESIs) provides support for ESIs with a program of research that aligns with the NIGMS mission.MIRA distributes funding among promising investigators across the country. The goal is to boost scientific productivity and the chances for important breakthroughs.Through this program, investigators can:Receive independent research funding early to start and sustain strong research careers.Explore new, unique research areas in the NIGMS mission.Take on ambitious, creative projects.Shift focus to include emerging techniques and technologies as needed.Devote more time to mentoring trainees in a stable research environment.
HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
Due Feb 9, 2029National Institutes of Health · Amount varies
The goal of this notice of funding opportunity (NOFO) is to address the opioid crisis and/or overdose events by supporting action-oriented research, accelerating the translation of addiction epidemiology, prevention, treatment services, and recovery research to practice. Proposed studies may target the individual, provider, organizational, community, or system level. This initiative prioritizes replicable and scalable approaches for accelerating the routine use of effective, evidence-based prevention, treatment and recovery interventions and services. The translation of research to practice and research relevant to chronic pain comorbid with substance use is also a priority. Research may deploy a variety of methods and approaches, including but not limited to identifying and characterizing malleable factors, developing and testing interventions and implementation strategies, deploying and testing collaborative data science approaches, and/or developing and testing approaches that integrate the collaboration of researchers and decision-makers at any levels (e.g., clinical-, health system-, public health- or policy-level).
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
Due Feb 20, 2029National Institutes of Health · Amount varies
The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing. This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress.
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Due Mar 5, 2029National Institutes of Health · $0–$250K
The National Library of Medicine (NLM) seeks applications for innovative research in clinical informatics. The overarching goal of this forthcoming program is to catalyze the development and advancement of novel informatics methodologies that empower clinicians, patients, and the broader public to better understand, manage, and improve health and health care delivery. This NOFO will support research focused on the design, implementation, and evaluation of clinical informatics tools and methods that enable data-driven discovery, promote evidence-based decision-making, and support personalized and precision health care. Emphasis will be placed on domain-independent, scalable, and reusable/reproducible approaches for the discovery, analysis, organization, and management of health-related digital objects—including electronic health records (EHRs), clinical notes, imaging data, and patient-generated data. The aim is to transform raw and heterogeneous health data into actionable knowledge, to develop innovative tools, and to implement practical applications that can be generalized across multiple clinical settings and populations. Projects should demonstrate the potential to accelerate scientific insights, improve clinical workflows, and ultimately lead to improved health outcomes.
Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)
Due Mar 5, 2029National Institutes of Health · Up to $250K
The National Library of Medicine (NLM) seeks applications for research projects that drive groundbreaking innovation and advanced development in the fields of bioinformatics, translational bioinformatics, and computational biology. The primary goal of this initiative is to support the creation and implementation of cutting-edge methods, tools, and approaches that can transform the landscape of biomedical data science. This NOFO aims to address the growing need to leverage transformative technologies — such as artificial intelligence (AI), machine learning, and large-scale computational platforms — to extract actionable knowledge from vast, diverse, and complex biological datasets. By enabling more effective interpretation and integration of multi-dimensional biological and biomedical data, this research will ultimately contribute to improving individual and population health outcomes.
Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Not Allowed)
Due Mar 12, 2029National Institutes of Health · Amount varies
The goal of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Notice of Funding Opportunity (NOFO) does not allow Scholars to propose to lead an independent clinical trial, but does allow Scholars to propose research experience in a clinical trial led by a mentor or co-mentor.
Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional)
Due Mar 16, 2029National Institutes of Health · Amount varies
The purpose of this notice of funding opportunity (NOFO) is to facilitate the entry of investigators into multiple high-priority areas of substance use research, including comorbidity with HIV. The Science Track Award for Research Transition (START) Program aims to provide investigators with the opportunity to gather preliminary data that will assist them in securing future research grants and advancing their scientific careers.
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
Due Apr 5, 2029National Institutes of Health · Amount varies
The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Due Apr 5, 2029National Institutes of Health · Amount varies
The Commercialization Readiness Pilot (CRP) program helps small business concerns (SBCs) move NIH-funded SBIR or STTR projects from late-stage development to commercialization. The CRP supports later-stage research and development (R&D) and/or technical assistance that Phase II and Phase IIB Strategic Breakthrough awards do not typically support. This includes:Independent replication or confirmation of key studiesIND- or IDE-enabling studiesClinical studiesManufacturing scale-up and related quality activitiesRegulatory and other specialized technical supportSBCs may subcontract (outsource) a significant amount of the work in a CRP to meet the project goals.
Predoctoral to Postdoctoral Transition Award (Parent F99/K00 - Clinical Trial Not Allowed)
Due Apr 8, 2029National Institutes of Health · Amount varies
The purpose of this award is to support promising graduate students as they complete their doctoral research training and transition into mentored postdoctoral career development opportunities in research areas relevant to the missions of participating NIH Institutes and Centers.This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.
NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed)
Due May 5, 2029National Institutes of Health · Amount varies
The National Institutes of Health (NIH) Research Education Program supports research education activities in the mission areas of the NIH. The overarching goal of the Research Education program is to:Support educational activities that complement and/or enhance training of a workforce to meet the nation's biomedical, behavioral and clinical research needs;Help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; and Foster a better understanding of biomedical, behavioral and clinical research and its implications.
NIH Research Educational Program - Mentoring Activities & Networks (Parent R25/UE5 - Clinical Trial Not Allowed)
Due May 5, 2029National Institutes of Health · Amount varies
The National Institutes of Health (NIH) Research Education Program supports research education activities in the mission areas of the NIH. The overarching goal of the Research Education program is to:Support educational activities that complement and/or enhance training of a workforce to meet the nation's biomedical, behavioral and clinical research needs;Help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; andFoster a better understanding of biomedical, behavioral and clinical research and its implications.
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)
Due May 7, 2029National Institutes of Health · Amount varies
The National Institutes of Health (NIH) seeks to advance its mission by maintaining strong, productive, and secure international research collaborations in support of the NIH mission. The NIH Collaborative International Research Project (Parent Announcement) supports international research collaborations. This opportunity specifically implements an award structure of prime domestic awards with independent foreign awards that are linked to the prime. This structure provides NIH with oversight capacity for international collaborations, and allows NIH to track international funding, as identified in NOT-OD-25-104. This funding opportunity is specifically designed for NIH to support funded international collaborations between a domestic prime organization and foreign organizations. This NOFO should not be used for foreign consultants, purchasing unique equipment or supplies from foreign vendors, foreign collaborations that do not involve NIH funding or any other foreign component that would not result in a foreign subaward. All collaborative international research project applications must include at least 1 international subproject. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes, Centers and Offices (ICOs) based on their scientific missions. The application will be evaluated as a whole, and the international subproject(s) will be evaluated on whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions in other countries that are not readily available in the United States or that augment existing United States resources, and whether the proposed project has specific relevance to the mission and objectives of the ICO and has the potential for significantly advancing the health sciences in the United States.
Biological Testing Facility for Contraception & Reproductive Health (X01 Clinical Trial Not Allowed)
Due May 7, 2029National Institutes of Health · Amount varies
The purpose of this notice of funding opportunity (NOFO) is to provide investigators with a mechanism to request services from the state-of-the-art Biological Testing Facility that would advance their contraceptive development or reproductive health programs. This NOFO aims to position innovative and validated methods for future regulatory submission and/or clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.
NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
Due May 25, 2029National Institutes of Health · Amount varies
This notice of funding opportunity (NOFO) invites submission of investigator-initiated Program Project (P01) applications. The proposed Programs should address scientific areas relevant to the NIAID mission including: biology and pathogenesis of infectious microbes, including HIV; host-microbe interactions; mechanisms regulating immune system development and function across the lifespan, and in response to infectious pathogens; immune dysfunction resulting in allergy, asthma, autoimmunity, immunodeficiency, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each application submitted to this NOFO must include at least two related, synergistic Research Projects that share a common central theme, focus, and/or overall objective; and an Administrative Core. An application may include Scientific Core(s), if needed for the proposed research.
NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)
Due May 25, 2029National Institutes of Health · Amount varies
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIH Science Education Partnership Award (SEPA) program is to support educational activities that increase understanding of biomedical research among pre-college (pre-kindergarten to grade12) individuals, and to encourage awareness of and continued interest in careers in science, technology, engineering, and mathematics (STEM).
NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
Due May 25, 2029National Institutes of Health · Amount varies
This notice of funding opportunity (NOFO) invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. This mechanism may also be used to support development of a new resource to the broader scientific community of the National Institute of Allergy and Infectious Diseases (NIAID). It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate.The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.